U.S. Severe Oral Mucositis Market, By Drug Type (Palifermin, Amifostine, Chlorhexidine, Sucralfate, Late Phase (Avasopasem and Dusquetide)), By Cause (Chemotherapy and Radiotherapy), By Grade (Grade III and Grade IV), By Distribution Channel (Hospital Pha

U.S. Severe Oral Mucositis Market, By Drug Type (Palifermin, Amifostine, Chlorhexidine, Sucralfate, Late Phase (Avasopasem and Dusquetide)), By Cause (Chemotherapy and Radiotherapy), By Grade (Grade III and Grade IV), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as well as increase the risk for local and systemic infection. Oral mucositis is a significant and dose-limiting toxicity of cancer therapy with important clinical and economic implications. Oral mucositis from chemotherapy or radiation treatment can last from 7 to 98 days.
Market Dynamics
The key players in the market are focused on growth strategies such as FDA approvals, which are expected to drive the growth of the market over forecast period. For instance, in November 2016, Oragenics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the company’s lead therapeutic candidate for the treatment of oral mucositis. Furthermore, in April 2018, Enzychem Lifesciences announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EC-18 for the treatment of chemo-radiation induced oral mucositis. Moreover, key companies focusing on research and development of severe oral mucositis are expected to drive the growth of the market over forecast period. For instance, in December 2019, Oragenics, Inc., announced the completion of enrolment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, which is an easy-to-use oral rinsing system designed to prevent and treat oral mucositis.
Key features of the study:
This report provides in-depth analysis of the U.S. severe oral mucositis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. severe oral mucositis market based on the following parameters – Company Highlights, financial performance, product portfolio, market presence, distribution strategies, Key Highlights, strategies, and future plans
Key companies covered as a part of this study include Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. severe oral mucositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. severe oral mucositis market.

Detailed Segmentation:
U.S. Severe Oral Mucositis Market, Drug Type:
Palifermin
Amifostine
Chlorhexidine
Sucralfate
Late Phase (Avasopasem, Dusquetide)
U.S. Severe Oral Mucositis Market, By Cause:
Chemotherapy
Radiotherapy
U.S. Severe Oral Mucositis Market, By Grade:
Grade III
Grade IV
U.S. Severe Oral Mucositis Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Hospital
Company Profiles
Innovation Pharmaceuticals Inc. *
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Monopar Therapeutics Inc.
Soligenix, Inc.
Oragenics, Inc.
Enzychem Lifesciences
Galera Therapeutics, Inc.
Amgen, Inc.
Covis Pharma Group

“*” marked represents similar segmentation in other categories in the respective section.